重组鼠CD20腺病毒载体感染的树突状细胞诱导小鼠抗肿瘤免疫的研究  

Immunization with dendritic cells infected with recombinant mouse CD20 adenovirus vector effectively elicits immunity against tumour

作　　者：王友臣[1] 谭晓华[1] 刘兵[1] 李慧[1] 王芳[1] 

机构地区：[1]北京军区总医院血液科

出　　处：《中华肿瘤防治杂志》2008年第7期507-510,共4页Chinese Journal of Cancer Prevention and Treatment

基　　金：首都医学发展科研基金资助项目(2005-2015)

摘　　要：目的:探讨复制缺损型腺病毒载体(adenovirus,Ad)介导的鼠CD20修饰的树突状细胞(dendritic cells,DCs)诱发抗肿瘤免疫的效果。方法:用AdmCD20感染小鼠骨髓来源的DC后,免疫C57BL/6小鼠,7d后取脾细胞行乳酸脱氢酶(lactate dehydrogenase,LDH)释放实验,检测特异性CTL杀伤活性;并给免疫小鼠接种经过筛选后表达mCD20基因的B16/F10肿瘤细胞,观察荷瘤小鼠成活情况。结果:AdmCD20/DCs免疫小鼠1周后其细胞毒性T淋巴细胞杀伤活性明显强于对照组(E∶T=100∶1,t=15·3354,P<0·01;E∶T=50∶1,t=14·2327,P<0·01;E∶T=10∶1,t=8·7444,P<0·01)。AdmCD20/DCs免疫小鼠1周后接种2×105个mCD20-B16/F10肿瘤细胞,2个月后仍有50%的小鼠无肿瘤生长;而对照组3周时全部有瘤生长,χ2=8·571,P<0·01。结论:AdmCD20修饰的DCs能有效地打破机体对肿瘤的免疫耐受,诱发强烈的抗原特异性细胞免疫应答。OBJECTIVE： To investigate the effects of dendritic cells（DCs） infected with recombinant adenovirus vector encoding mCD20 on breaking the immune tolerance and induction of immunity against tumour. METHODS： C57BL/6 mice were immunized with recombinant AdmCD20 infected DCs isolated from the C57BL/6 mouse bone marrow and in vitro CTL activity against tumor cells was examined by LDH release assay after 7 day. Survival of the immunized mice inoculated with mCD20-B16/F10 cells was studied. RESULTS： The activity of CTL elicited by the recombinant AdmCD20 infected DCs were much stronger than control group （E ： T= 100 ： 1, t= 15. 335 4, P〈 0.01; E： T=50 ： 1, t=14.232 7, P〈0.01;E： T=10 ： 1, t= 8. 744 4, P〈0. 01）. 60% of the recombinant AdmCD20/DCs immunized mice of the inoculated with 2 × 10^5 mCD20-B16/F10 cells were still alive without tumor two months after inoculation. However, 100% mice have tumor growth in the control group 18 day later, Х^2=8. 571, P〈0.01. CONCLUSION： Recombinant adenovirus vector mediated mCD20 infected DCs can effectively break the immune tolerance of tumor in an animal model and induce strong antigen specific T cell response.

关 键 词：腺病毒科 抗原 CD20 树突细胞 淋巴瘤 

分 类 号：R730.51[医药卫生—肿瘤]